Indication

For treatment of severe and moderately severe haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors.

Medicine details

Medicine name:
etranacogene dezaparvovec (Hemgenix)
SMC ID:
SMC2649
Pharmaceutical company
CSL Behring
BNF chapter
Nutrition and blood
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
TBC